Continuous infusion versus intermittent bolus injection of bleomycin in a human embryonal testicular cancer xenograft.
In vivo experiments with bleomycin in conventional murine tumor systems indicate a superiority of continuous-infusion schedules over daily intermittent bolus injections. This schedule of administration has been incorporated into many clinical trials, especially in testicular cancer, on the basis of in vitro and in vivo experiments as well as favorable comparisons with historical controls. Since mechanisms linked to a superiority of continuous-infusion schedules may not be operative in every individual tumor line, we have compared both schedules of administration in a human testicular cancer xenograft. We found no significant difference with respect to antineoplastic response.
D000818:Animals; D001761:Bleomycin / Q000008:administration & dosage*; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D013724:Teratoma / Q000188:drug therapy* / Q000473:pathology; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology
D001761:Bleomycin